March 2022 - Biologics by McKesson

VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson

Mar 15, 2022 | Press Release

CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by CTI BioPharma Corp. as a specialty pharmacy provider for VONJO™ (pacritinib) for the treatment of intermediate or...

PYRUKYND (mitapivat), FDA Approved for Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency, Available Exclusively at Biologics by McKesson

Mar 2, 2022 | Press Release

CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Agios Pharmaceuticals, Inc. as a specialty pharmacy provider for PYRUKYND® (mitapivat) for the treatment of hemolytic...

VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson

PYRUKYND (mitapivat), FDA Approved for Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency, Available Exclusively at Biologics by McKesson

Recent Posts

Archives